U.S. Physical Therapy (NYSE:USPH) was upgraded by equities research analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a note issued to investors on Monday, Analyst Ratings Network reports. The brokerage currently has a $135.00 price target on the stock, up from their previous price target of $130.00. Jefferies Financial Group’s price target would indicate a potential upside of 16.32% from the stock’s current price. Jefferies Financial Group also issued estimates for U.S. Physical Therapy’s Q2 2021 earnings at $0.74 EPS, Q3 2021 earnings at $0.71 EPS, Q4 2021 earnings at $0.75 EPS, Q1 2022 earnings at $0.68 EPS, Q2 2022 earnings at $0.76 EPS, Q3 2022 earnings at $0.73 EPS, Q4 2022 earnings at $0.77 EPS, Q1 2023 earnings at $0.67 EPS and FY2023 earnings at $3.27 EPS.
Other analysts have also issued reports about the stock. Barrington Research reissued a “market perform” rating on shares of U.S. Physical Therapy in a research report on Thursday, March 4th. Zacks Investment Research lowered shares of U.S. Physical Therapy from a “hold” rating to a “strong sell” rating in a research report on Wednesday, April 28th.
Shares of U.S. Physical Therapy stock opened at $116.06 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.89 and a quick ratio of 0.89. U.S. Physical Therapy has a 1 year low of $64.30 and a 1 year high of $143.67. The firm’s 50-day moving average is $111.40 and its two-hundred day moving average is $114.39. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of 49.39 and a beta of 1.45.
In other U.S. Physical Therapy news, CFO Lawrance W. Mcafee sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, March 5th. The shares were sold at an average price of $110.76, for a total transaction of $553,800.00. Also, COO Graham D. Reeve sold 1,200 shares of the firm’s stock in a transaction that occurred on Monday, March 1st. The stock was sold at an average price of $116.50, for a total transaction of $139,800.00. The disclosure for this sale can be found here. Insiders sold a total of 10,800 shares of company stock valued at $1,246,748 over the last ninety days. 2.00% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Fieldpoint Private Securities LLC raised its position in U.S. Physical Therapy by 4,740.0% during the 1st quarter. Fieldpoint Private Securities LLC now owns 242 shares of the company’s stock worth $25,000 after buying an additional 237 shares during the last quarter. Vantage Consulting Group Inc acquired a new stake in shares of U.S. Physical Therapy during the 4th quarter worth approximately $27,000. Wolff Wiese Magana LLC acquired a new stake in shares of U.S. Physical Therapy during the 4th quarter worth approximately $35,000. Veriti Management LLC acquired a new stake in shares of U.S. Physical Therapy during the 4th quarter worth approximately $68,000. Finally, Nisa Investment Advisors LLC grew its stake in shares of U.S. Physical Therapy by 44.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 650 shares of the company’s stock worth $78,000 after purchasing an additional 200 shares during the period.
U.S. Physical Therapy Company Profile
U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.
Featured Article: What is the S&P/TSX Index?
Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.